Cassidy’s 340B Reform Draft: What Every Covered Entity Needs to Know

For the first time in years, a sitting Senate committee chairman has put comprehensive 340B reform legislation on the table. In June 2026, Sen. Bill Cassidy (R-LA), Chairman of the Senate Health, Education, Labor and Pensions (HELP) Committee, released a formal discussion draft proposing sweeping changes to the 340B Drug Pricing Program. If you run a Ryan White clinic, an STD clinic, or any 340B-covered entity, this is not background noise — it is a signal that the regulatory ground under your program is shifting.

What the Cassidy Discussion Draft Proposes

Cassidy’s draft is explicitly framed as a fix to what he characterizes as a program that has drifted from its original purpose: helping low-income and uninsured patients access affordable prescription drugs. Key provisions in the draft discussion include:

• Increased transparency requirements for how covered entities use 340B savings
• Restrictions on contract pharmacy arrangements, building on the manufacturer restrictions already in place
• New patient eligibility definitions that could narrow who counts as a 340B-eligible patient
• Enhanced HRSA oversight and audit authority
• Potential caps or reporting requirements on the spread between 340B acquisition cost and reimbursement

The draft does not have the force of law yet — it is a discussion document intended to solicit feedback from stakeholders. But discussion drafts from HELP Committee chairs carry significant weight. They become the starting point for markup sessions and, eventually, legislation.

Why This Matters for Ryan White Clinics and STD Programs

Ryan White grantees and STD clinics are among the most mission-aligned 340B participants — and that matters in this political environment. The criticism aimed at the 340B program has largely been directed at large hospital systems that use contract pharmacies to generate significant revenue. Clinics that can demonstrate direct patient benefit from their 340B savings are in a defensible position.

That said, any change to patient eligibility definitions, contract pharmacy rules, or the definition of a qualifying 340B entity will directly affect clinic operations for covered entities of all sizes.

The PIAP Connection: Reducing Dependency Before the Rules Change

A Premium Insurance Assistance Program (PIAP) uses a portion of a clinic’s 340B savings to pay commercial insurance premiums for eligible patients. If the Cassidy draft moves forward and narrows the 340B savings pool, clinics with an established premium insurance program already have a parallel revenue stream in place. They have a patient population enrolled in commercial insurance, active payer relationships, and operational billing infrastructure that continues to generate revenue regardless of what happens to 340B.

American Exchange works exclusively with Ryan White clinics and 340B covered entities to design and operate PIAPs. We help clinics analyze their patient population, select the right insurance plans, manage enrollment, and connect 340B savings to premium payments — all within compliant guardrails.

Schedule time to meet with our team to discuss.